vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Metallus Inc. (MTUS). Click either name above to swap in a different company.
Metallus Inc. is the larger business by last-quarter revenue ($267.3M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -5.3%, a 16.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 11.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-37.2M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -8.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANIP vs MTUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $267.3M |
| Net Profit | $27.5M | $-14.3M |
| Gross Margin | — | 2.2% |
| Operating Margin | 14.1% | -7.7% |
| Net Margin | 11.1% | -5.3% |
| Revenue YoY | 29.6% | 11.1% |
| Net Profit YoY | 367.5% | 33.2% |
| EPS (diluted) | $1.14 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $267.3M | ||
| Q3 25 | $227.8M | $305.9M | ||
| Q2 25 | $211.4M | $304.6M | ||
| Q1 25 | $197.1M | $280.5M | ||
| Q4 24 | $190.6M | $240.5M | ||
| Q3 24 | $148.3M | $227.2M | ||
| Q2 24 | $138.0M | $294.7M | ||
| Q1 24 | $137.4M | $321.6M |
| Q4 25 | $27.5M | $-14.3M | ||
| Q3 25 | $26.6M | $8.1M | ||
| Q2 25 | $8.5M | $3.7M | ||
| Q1 25 | $15.7M | $1.3M | ||
| Q4 24 | $-10.3M | $-21.4M | ||
| Q3 24 | $-24.2M | $-5.9M | ||
| Q2 24 | $-2.3M | $4.6M | ||
| Q1 24 | $18.2M | $24.0M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 11.4% | ||
| Q2 25 | — | 10.6% | ||
| Q1 25 | — | 7.8% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 15.7% |
| Q4 25 | 14.1% | -7.7% | ||
| Q3 25 | 15.9% | 3.6% | ||
| Q2 25 | 6.6% | 2.8% | ||
| Q1 25 | 13.3% | 1.0% | ||
| Q4 24 | -2.3% | -10.1% | ||
| Q3 24 | -13.8% | -3.1% | ||
| Q2 24 | 3.7% | 2.1% | ||
| Q1 24 | 14.8% | 9.3% |
| Q4 25 | 11.1% | -5.3% | ||
| Q3 25 | 11.7% | 2.6% | ||
| Q2 25 | 4.0% | 1.2% | ||
| Q1 25 | 8.0% | 0.5% | ||
| Q4 24 | -5.4% | -8.9% | ||
| Q3 24 | -16.3% | -2.6% | ||
| Q2 24 | -1.7% | 1.6% | ||
| Q1 24 | 13.2% | 7.5% |
| Q4 25 | $1.14 | $-0.34 | ||
| Q3 25 | $1.13 | $0.19 | ||
| Q2 25 | $0.36 | $0.09 | ||
| Q1 25 | $0.69 | $0.03 | ||
| Q4 24 | $-0.45 | $-0.46 | ||
| Q3 24 | $-1.27 | $-0.13 | ||
| Q2 24 | $-0.14 | $0.10 | ||
| Q1 24 | $0.82 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $156.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $686.0M |
| Total Assets | $1.4B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $156.7M | ||
| Q3 25 | $262.6M | $191.5M | ||
| Q2 25 | $217.8M | $190.8M | ||
| Q1 25 | $149.8M | $180.3M | ||
| Q4 24 | $144.9M | $240.7M | ||
| Q3 24 | $145.0M | $254.6M | ||
| Q2 24 | $240.1M | $272.8M | ||
| Q1 24 | $228.6M | $278.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $5.4M | ||
| Q4 24 | — | $5.4M | ||
| Q3 24 | — | $13.2M | ||
| Q2 24 | — | $13.2M | ||
| Q1 24 | — | $13.2M |
| Q4 25 | $540.7M | $686.0M | ||
| Q3 25 | $505.8M | $697.7M | ||
| Q2 25 | $436.8M | $690.0M | ||
| Q1 25 | $418.6M | $686.1M | ||
| Q4 24 | $403.7M | $690.5M | ||
| Q3 24 | $405.9M | $712.7M | ||
| Q2 24 | $455.8M | $736.3M | ||
| Q1 24 | $452.0M | $739.3M |
| Q4 25 | $1.4B | $1.1B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-1.9M |
| Free Cash FlowOCF − Capex | $29.1M | $-37.2M |
| FCF MarginFCF / Revenue | 11.8% | -13.9% |
| Capex IntensityCapex / Revenue | 0.5% | 13.2% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-1.9M | ||
| Q3 25 | $44.1M | $22.0M | ||
| Q2 25 | $75.8M | $34.8M | ||
| Q1 25 | $35.0M | $-38.9M | ||
| Q4 24 | $15.9M | $13.9M | ||
| Q3 24 | $12.5M | $-15.3M | ||
| Q2 24 | $17.4M | $8.3M | ||
| Q1 24 | $18.3M | $33.4M |
| Q4 25 | $29.1M | $-37.2M | ||
| Q3 25 | $38.0M | $-6.4M | ||
| Q2 25 | $71.8M | $17.0M | ||
| Q1 25 | $32.5M | $-66.4M | ||
| Q4 24 | $13.5M | $-1.3M | ||
| Q3 24 | $7.7M | $-32.9M | ||
| Q2 24 | $13.0M | $-5.8M | ||
| Q1 24 | $13.7M | $16.0M |
| Q4 25 | 11.8% | -13.9% | ||
| Q3 25 | 16.7% | -2.1% | ||
| Q2 25 | 34.0% | 5.6% | ||
| Q1 25 | 16.5% | -23.7% | ||
| Q4 24 | 7.1% | -0.5% | ||
| Q3 24 | 5.2% | -14.5% | ||
| Q2 24 | 9.4% | -2.0% | ||
| Q1 24 | 10.0% | 5.0% |
| Q4 25 | 0.5% | 13.2% | ||
| Q3 25 | 2.7% | 9.3% | ||
| Q2 25 | 1.9% | 5.8% | ||
| Q1 25 | 1.3% | 9.8% | ||
| Q4 24 | 1.3% | 6.3% | ||
| Q3 24 | 3.2% | 7.7% | ||
| Q2 24 | 3.2% | 4.8% | ||
| Q1 24 | 3.3% | 5.4% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 2.72× | ||
| Q2 25 | 8.87× | 9.41× | ||
| Q1 25 | 2.23× | -29.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.80× | ||
| Q1 24 | 1.00× | 1.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MTUS
| Industrial Market Sector | $95.3M | 36% |
| Manufactured Components | $67.8M | 25% |
| Aerospace And Defense | $39.6M | 15% |
| Seamless Mechanical Tubing | $31.3M | 12% |
| Energy Market Sector | $18.3M | 7% |
| Other | $11.3M | 4% |
| Other Market Sector | $3.7M | 1% |
